E-LIB Suche - Ergebnisse für: Formica, Neil

1

Strong CD4+ T-Cell Responses to Ancestral and Variant Spike..:

Fries, Louis ; Formica, Neil ; Mallory, Raburn M...
The Journal of Infectious Diseases. 228 (2023) 6 - p. 734-741 , 2023

Link: https://doi.org/10.1093/..

2

Different dose regimens of a SARS-CoV-2 recombinant spike p..:

Formica, Neil ; Mallory, Raburn ; Albert, Gary...
PLOS Medicine. 18 (2021) 10 - p. e1003769 , 2021

Link: https://doi.org/10.1371/..

3

Immunogenicity and safety of a quadrivalent inactivated inf..:

Treanor, John T. ; Albano, Frank R. ; Sawlwin, Daphne C....
Vaccine. 35 (2017) 15 - p. 1856-1864 , 2017

Link: https://doi.org/10.1016/..

4

Immunogenicity and safety of a quadrivalent inactivated inf..:

Airey, Jolanta ; Albano, Frank R. ; Sawlwin, Daphne C....
Vaccine. 35 (2017) 20 - p. 2745-2752 , 2017

Link: https://doi.org/10.1016/..

5

Randomized Study to Compare Immunogenicity and Safety of Se..:

Leong, Jane ; Sawlwin, Daphne ; Graves-Jones, Alison...
Open Forum Infectious Diseases. 3 (2016) suppl_1 - p. , 2016

Link: https://doi.org/10.1093/..

6

Population Seroprevalence of Human Papillomavirus Types 6, ..:

Newall, Anthony T. ; Brotherton, Julia M. L. ; Quinn, Helen E....
Clinical Infectious Diseases. 46 (2008) 11 - p. 1647-1655 , 2008

Link: https://doi.org/10.1086/..

7

Population Seroprevalence of Human Papillomavirus Types 6, ..:

Newall, Anthony T. ; Brotherton, Julia M. L. ; Quinn, Helen E....
Clinical Infectious Diseases. 46 (2008) 11 - p. 1647-1655 , 2008

Link: https://www.jstor.org/st..

8

Immunogenicity, safety and consistency of new trivalent ina..:

Talbot, H. Keipp ; Keitel, Wendy ; Cate, Thomas R....
Vaccine. 26 (2008) 32 - p. 4057-4061 , 2008

Link: https://doi.org/10.1016/..

9

Abattoir‐associated Q fever: a Q fever outbreak during a Q ..:

Gilroy, Nicole ; Formica, Neil ; Beers, Mary...
Australian and New Zealand Journal of Public Health. 25 (2001) 4 - p. 362-367 , 2001

Link: https://doi.org/10.1111/..

10

Phase I and II randomised trials of the safety and immunoge..:

Nolan, Terry M. ; Richmond, Peter C. ; Skeljo, Maryanne V....
Vaccine. 26 (2008) 33 - p. 4160-4167 , 2008

Link: https://doi.org/10.1016/..

11

Safety and immunogenicity of a prototype adjuvanted inactiv..:

Nolan, Terry ; Richmond, Peter C. ; Formica, Neil T....
Vaccine. 26 (2008) 50 - p. 6383-6391 , 2008

Link: https://doi.org/10.1016/..

12

Safety and immunogenicity following a homologous booster do..:

Mallory, Raburn M ; Formica, Neil ; Pfeiffer, Susan...
The Lancet Infectious Diseases. , 2022

Link: http://hdl.handle.net/10..

13

Immunogenicity, Safety and Consistency Of New Trivalent Ina..:

Talbot, H. Keipp ; Keitel, Wendy ; Cate, Thomas R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605420. , 2008

Link: http://www.ncbi.nlm.nih...

14

Different dose regimens of a SARS-CoV-2 recombinant spike p..:

Neil Formica ; Raburn Mallory ; Gary Albert...
https://doi.org/10.1371/journal.pmed.1003769. , 2021

Link: https://doi.org/10.1371/..

15

Demographic characteristics of the participants at enrollme..:

Neil Formica (11512548) ; Raburn Mallory (11512551) ; Gary Albert (11512554)...
https://figshare.com/articles/dataset/Demographic_characteristics_of_the_participants_at_enrollment_Safety_Analysis_Set_/16723176. , 2021

Link: https://doi.org/10.1371/..